Researchers from the Summa Health Sytem, IC-MedTech and other institutions have announced completion of the first ever FDA approve human clinical trial of Apatone. Apatone uses a new strategy to selectively lower the level of compounds within tumor cells. These compounds assist in the production of energy and protect the tumor against chemotherapy. Results are promising in that the non-toxic method weakens and kills cancers in a new way.
"This strategy targets cancer cells by their inflammatory response," explains Dr. Jamison, developer of Apatone. "It's a different approach than most other anti-tumor drugs, which target dividing cells or the development of blood vessels within the tumor. Since normal cells use sugars or fats for energy and cancer cells rely on glucose, the real key here is that Apatone resembles glucose. As Apatone preferentially accumulates in cancer cells, it also supplies quinone that weakens and can destroy the cancer cell from within. The bottom line is: Apatone selectively targets and kills tumor cells using non-toxic biochemistry that protects surrounding healthy tissue."
The intent is to administer Apatone intravenously, prior to chemotherapy, so that it can breakdown the compounds in the tumor that protect it from the chemo. However, FDA approval has not been awarded for this combination treatment.
[Source: SummaHealth]
Comment Preview